CSL confirms its earnings will decline by approximately 4% due to ongoing structural issues, as EMVision expands stroke detection trials.
Health Check by Tim Boreham: CSL confirms earnings will fall around 4% as structural problems mount, while EMVision Medical Devices broadens its stroke detection trial to include ischaemic strokes. #ASX #Biotech $CSL $EMV
